Rare disease market entry in Switzerland

Switzerland is often perceived as a “small market” – which sometimes leads to one of two extremes: being deprioritised, or being overengineered from day one.

Based on our experience, successful rare disease launches in Switzerland are not about size or complexity, but about making the right decisions at the right time.

A smart entry to the Swiss market takes a holistic view and considers:

• Swissmedic regulatory requirements

• market access pathways and reimbursement strategy

• lean local setup with internal and external roles aligned

• launch readiness across medical, access and commercial areas

Especially in rare diseases, building focused, flexible and fit‑for‑purpose structures often has more impact than building big.

Switzerland rewards clarity, preparation and pragmatism.

This is exactly where we at Swizzard support companies as they navigate rare disease market entry in Switzerland.

Planning a rare disease launch in Switzerland? Let’s start the conversation.

---

Reach out to us for expert guidance on your strategic planning. Together, we can ensure a smooth regulatory and market access process, accelerating the availability of rare disease therapies to patients in need.

Michael Zürcher, Owner & CEO

Annabelle Müller, Market Access Director

Contact Us